Peptide-anchored neutrophil membrane-coated biomimetic nanodrug for targeted treatment of rheumatoid arthritis

Journal of Nanobiotechnology

Research

Shi Yu¹  Xinzhi Li¹  Yingying Wan²  Xiang Yu²  Ni Yang²  Baoye Yang²  Miaomiao Li²  Wenjing Cheng²  Xiaoqin Mou²  Hong Yu²  Yinhong Song³  Ling Wu⁴  Jing Zheng⁴ 

[1] College of Basic Medical Science, China Three Gorges University, 443002, Yichang, China;Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, 443002, Yichang, China;Institute of Infection and Inflammation, China Three Gorges University, 443002, Yichang, China;College of Basic Medical Science, China Three Gorges University, 443002, Yichang, China;Institute of Infection and Inflammation, China Three Gorges University, 443002, Yichang, China;College of Basic Medical Science, China Three Gorges University, 443002, Yichang, China;The People’s Hospital of China Three Gorges University, 443099, Yichang, China;

关键词: Neutrophil;    Rheumatoid arthritis;    Macrophage;    Nanodrug;    Target therapy;   

DOI  :  10.1186/s12951-023-01773-x

 received in 2022-10-27, accepted in 2023-01-08,  发布年份 2023

来源: Springer

【 摘 要 】

Macrophage polarization determines the production of cytokines that fuel the initiation and evolution of rheumatoid arthritis (RA). Thus, modulation of macrophage polarization might represent a potential therapeutic strategy for RA. However, coordinated modulation of macrophages in the synovium and synovial fluid has not been achieved thus far. Herein, we develop a biomimetic ApoA-I mimetic peptide-modified neutrophil membrane-wrapped F127 polymer (R4F-NM@F127) for targeted drug delivery during RA treatment. Due to the high expression of adhesion molecules and chemokine receptors on neutrophils, the neutrophil membrane coating can endow the nanocarrier with synovitis-targeting ability, with subsequent recruitment to the synovial fluid under the chemotactic effects of IL-8. Moreover, R4F peptide modification further endows the nanocarrier with the ability to target the SR-B1 receptor, which is highly expressed on macrophages in the synovium and synovial fluid. Long-term in vivo imaging shows that R4F-NM@F127 preferentially accumulates in inflamed joints and is engulfed by macrophages. After loading of the anti-inflammatory drug celastrol (Cel), R4F-NM@F127-Cel shows a significant reduction in hepatotoxicity, and effectively inhibits synovial inflammation and alleviates joint damage by reprogramming macrophage polarization. Thus, our results highlight the potential of the coordinated targeted modulation of macrophages as a promising therapeutic option for the treatment of RA.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

41116_2022_35_Article_IEq66.gif

41116_2022_35_Article_IEq57.gif

Fig. 9

41116_2022_35_Article_IEq29.gif

41116_2022_35_Article_IEq21.gif

41116_2022_35_Article_IEq11.gif

Fig. 2

Fig. 1